The Digital Transformation of Cancer Care

Anastassia Negrouk is Chief Operating Officer, MyData-Trust Anastassia is a certified DPO... Anastassia Negrouk is Chief Operating Officer, MyData-Trust Anastassia is a certified DPO (@Solvay), COO at MyData-Trust, specialised in GDPR compliance in life sciences with almost 20 years of experience in clinical cancer research, she has been closely following the development and implementation of EU directives and regulations relevant to clinical research, such as data protection regulation, clinical trials regulation, in-vitro medical device regulation, etc. She is regularly monitoring, analysing and publishing on potential impact of these regulations on life science sector, with a specific interest in international clinical research. This deep knowledge of legislation and clinical research realities can also support negotiation of contracts and set-up of partnerships, thus another field of Anastassia's expertise that can support set-up of collaborations in the scope of international, including transatlantic, clinical trials, large EU consortiums (e.g. in the scope of EU funded projects) and patient involvement initiatives. Excellent speaker, Anastassia is frequently taking part in international meetings and conferences in the domain. Anastassia Negrouk is holding master's degree in Biology, she specialised during 5 years in cellular biology and biochemistry working in a university research laboratory focusing on cancer research and thereafter joint EORTC in 2000 to specialise in regulatory affairs and policy. After almost 20 years at EORTC from which three years as DPO, Anastassia joined MyData-Trust to bring her expertise to the service at the service of organisations active in life science. Read more Show less

Gilly Spurrier-Bernard is Vice-Chair, Patient Advisory Committee, European Cancer... Gilly Spurrier-Bernard is Vice-Chair, Patient Advisory Committee, European Cancer Organisation Member, European Cancer Organisation's Patient Advisory Committee, Chair, WECAN and Member, Melanoma Patient Network Europe. A Geologist/Environmental Scientist by training, she began in Advocacy when her husband became a stage 4 Melanoma Patient in 2008. 2014-Present - President of MelanomeFrance - a patient Association run by volunteer Patients/Carers that provides up to date information on Melanoma Disease, Treatments, Clinical trials, Health Systems, Side Effect management and survivorship, as well as support for patients and their families. Moderation of a Forum of >900 Francophone Patients/Carers. Contributions to HTA evaluations for the HAS (French Evaluator), Contribution to selection of INCa Funded Projects, Lobbying of Stakeholders for access to treatments and clinical research. Contribution to research projects into PROs, Microbiome, rare cancers. 2016-Present - Vice-present of Melanoma Patient Network Europe - Participation in several initiatives, (Horizon 2020, IMI Get real, PRO research, and several European Projects) Planning and running several Patient and Multi-stakeholder Congresses each year : European, Regional, National, special group (Rare Melanoma s and paediatric) and Pan-Cancer meetings. Meetings and Advisory boards with all stakeholders: Regulators, HTA, Industry, Clinicians and Health Economists. 2019-Present - Chair of WECAN - Co-ordinating and communicating the joint activities/initiatives of 22 Pan-Cancer umbrella Organizations – Planning and Contributing the annual WECAN Academy for Cancer Patient Advocates, In January 2020 planned and ran the first WECAN Science training for Cancer patient advocates EUPATI fellow, Member of the European Cancer Organisation's Patient Advisory Committee, Project Partner on 2 Horizon 2020 Projects, Speaker at ESMO, the European Cancer Summit, EHA, several European Patient Conferences on topics from Fertility and Cancer, Combatting Pseudoscience, Immunotherapy Side effects, Value Frameworks and many more. Contributing to several publications : The European Cancer Organisation Essential Requirement for Quality Cancer Care in Melanoma, ASCO Melanoma Treatment Guidelines, ESMO Patient Guide for Immunotherapy Side Effects. I am passionate about patient education because well-informed patients are best equipped to lead the decision making in their treatment and hence cope better with their life as a melanoma patient/carer. I believe that Patient Advocates can drive better Patient relevant research through direct access to the primary data source and collaboration with other useful stakeholders. Read more Show less

Professor and Chair, Department of Biomedical Informatics, Professor of Radiology, University of... Professor and Chair, Department of Biomedical Informatics, Professor of Radiology, University of Arkansas for Medical Sciences Read more Show less

EU Cancer Mission Board Member, Member of the European Cancer Organisation Executive Committee,... EU Cancer Mission Board Member, Member of the European Cancer Organisation Executive Committee, Digital Health Network Co-Chair Read more Show less

Professor Wim Oyen is Treasurer, European Cancer Organisation and Digital Health Network... Professor Wim Oyen is Treasurer, European Cancer Organisation and Digital Health Network Co-Chair. He is nuclear medicine physician at the Department of Radiology and Nuclear Medicine of Rijnstate Hospital, Arnhem, The Netherlands and full Professor of Diagnostic Imaging and Radiotherapy at Humanitas University in Milan, Italy. From 2015-2018, he was full Professor of Nuclear Medicine and Molecular Imaging at The Institute of Cancer Research and Head of the Department of Nuclear Medicine of The Royal Marsden Hospital, London, UK. Before working in the UK, he was a nuclear medicine physician and full Professor of Nuclear Medicine at the Radboud University Medical Centre Nijmegen, The Netherlands, serving as Head of the Department of Nuclear Medicine, Member of the Board of the Medical Staff and Director of the Research Institute for Oncology of RadboudUMC. Professor Oyen’s main research interests are molecular imaging in oncology and infectious diseases and radionuclide therapy of cancer. He is the (co-)author of more than 650 original science and review articles in international peer-reviewed journals. He is currently actively involved in the European Association of Nuclear Medicine (Board Member 2014-2020, past-Congress Chair 2015-2017 and EANM President 2019-2020), the International Cancer Imaging Society (member of the Board and the Trustees 2016-present, President 2017-2018) and in the European Cancer Organisation (Board member 2012-2016 and 2020-present, Treasurer 2014-2015, 2020-2021). Professor Oyen is a member of several Editorial Boards, including the European Journal of Nuclear Medicine and Molecular Imaging and the Journal of Nuclear Medicine. Read more Show less

Principal Investigator, Radiology & Nuclear Medicine, Erasmus MC